Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.08. | Egetis Therapeutics: Aktie steigt nach Q2-Zahlen trotz verfehlter Umsatzprognose | 1 | Investing.com Deutsch | ||
21.08. | Egetis Therapeutics AB: Interim report Q2 2025 | 75 | GlobeNewswire (Europe) | Egetis reports progress towards US NDA submission for tiratricol· FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis... ► Artikel lesen | |
18.08. | Egetis Therapeutics AB: Egetis reports progress towards US NDA submission for tiratricol | 338 | GlobeNewswire (Europe) | FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis of the survival data set from the international real-world cohort study by... ► Artikel lesen | |
15.07. | Egetis Therapeutics AB: Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency | 198 | GlobeNewswire (Europe) | Stockholm, Sweden, July 15, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough... ► Artikel lesen | |
05.05. | Egetis Therapeutics AB: Egetis Confirms Launch of Emcitate in Germany | 372 | GlobeNewswire (Europe) | For investors and media only
Stockholm, Sweden, May 5, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), a pharmaceutical company dedicated to developing therapies... ► Artikel lesen | |
30.04. | Egetis Therapeutics AB: Interim report Q1 2025 | 88 | GlobeNewswire (Europe) | Egetis plans to launch Emcitate® in the first country, Germany, on May 1, 2025The European Commission approved Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency.In... ► Artikel lesen | |
EGETIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
26.02. | Egetis Therapeutics AB: Year-End Report January-December 2024 | 259 | GlobeNewswire (Europe) | European Commission has approved Egetis' Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency· Egetis expects to launch Emcitate in the first country, Germany... ► Artikel lesen | |
13.02. | Egetis Therapeutics AB: European Commission approves Egetis' Emcitate (tiratricol) as the first and only treatment for patients with MCT8 deficiency | 277 | GlobeNewswire (Europe) | Stockholm, Sweden, February 13, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol)... ► Artikel lesen | |
08.11.24 | Egetis Therapeutics AB: Interim report Q3 2024 | 189 | GlobeNewswire (Europe) | Egetis successfully carried out directed share issuances amounting to SEK 300 million· The Company's MAA review for tiratricol (Emcitate®) at the EMA remains on track according to EMA's stipulated... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SANOFI | 80,50 | +0,12 % | UBS stuft SANOFI auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Sanofi auf "Buy" mit einem Kursziel von 115 Euro belassen. Sanofi sei das günstigste große EU-Pharmaunternehmen und werde... ► Artikel lesen | |
GSK | 17,450 | -0,91 % | Research and Markets: Europe Liver Disease Therapeutic Market Analysis Report 2025-2033 Featuring Abbott, Astellas, BMS, Gilead Sciences, GSK, F. Hoffman-La Roche, Merck & Co., Novartis, Sanofi, Pfizer, Takeda - ResearchAndMarkets.com | The "Europe Liver Disease Therapeutic Market Forecast 2025" report has been added to ResearchAndMarkets.com's offering.
The Europe Liver Disease Therapeutic Market is expected to grow from US$... ► Artikel lesen | |
ASTRAZENECA | 136,55 | -1,34 % | AstraZeneca erzielt Durchbruch bei Lungenkrebs-Studie | AstraZeneca hat in einer großen Phase-III-Studie (FLAURA2) neue Erfolge mit seinem Lungenkrebsmittel Tagrisso gemeldet. In Kombination mit einer platinhaltigen Chemotherapie und Pemetrexed verlängerte... ► Artikel lesen | |
TILRAY BRANDS | 0,963 | +0,67 % | Tilray Brands, Inc. - 8-K, Current Report | ||
DERMAPHARM | 32,950 | +0,61 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm mit einem Kursziel von 34 Euro auf "Hold" belassen. Das Management sei zuversichtlich hinsichtlich des Ergebnisziels... ► Artikel lesen | |
QUANTUM BIOPHARMA | 14,600 | -1,35 % | Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target | TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
TONIX PHARMACEUTICALS | 24,400 | 0,00 % | Stocks Moving Premarket: Propanc Biopharma, BTAI, Tonix Pharmaceuticals, Dayforce, TPI Composites, And Other Gainers & Losers | OTTAWA (dpa-AFX) - At 6.50 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
CASSAVA SCIENCES | 1,874 | +4,49 % | CASSAVA SCIENCES INC - 8-K, Current Report | ||
OPKO HEALTH | 1,240 | +3,58 % | Here's Why You Should Retain OPKO Health Stock in Your Portfolio | ||
SELLAS LIFE SCIENCES | 1,620 | +2,40 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
SOLIGENIX | 2,930 | +5,40 % | Stocks Moving Premarket: Viking Therapeutics, Flexsteel Industries, Propanc Biopharma, Soligenix And Other Gainers & Losers | CANBERA (dpa-AFX) - At 8.20 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
BETTERLIFE PHARMA | 0,047 | 0,00 % | BETTERLIFE HLDG (06909): 2025 INTERIM REPORT | ||
THERIVA BIOLOGICS | 0,425 | +1,29 % | Theriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results | - Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress... ► Artikel lesen | |
NOVABAY PHARMACEUTICALS | 2,590 | -12,50 % | Stocks Moving Premarket: NovaBay Pharmaceuticals, Auddia, Propanc Biopharma And Other Gainers & Losers | CANBERA (dpa-AFX) - At 7:15 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
BAYER | 28,070 | -2,64 % | Bayer-Aktie mit Kursverlusten (27,985 €) | Im deutschen Wertpapierhandel notiert das Wertpapier von Bayer gegenwärtig etwas leichter. Der jüngste Kurs betrug 27,99 Euro. Das Wertpapier von Bayer verzeichnet derzeit einen Kursrückgang von 0,60... ► Artikel lesen |